GSK nabs FDA greenlight for second lung cancer asset from Nuvalent buy

Nelkarmi is one of two bounties from GSK’s $10.6 billion acquisition of Nuvalent Bio—the other being the ROS1 inhibitor zidesamtinib, which won FDA approval earlier this year as Jideytro.

The FDA has granted accelerated approval to GSK’s tyrosine kinase inhibitor neladalkib for ALK-positive non-small cell lung cancer, marking the second regulatory win from the pharma’s $10.6 billion takeover of Nuvalent Bio earlier this year.

The approval, which came 10 days ahead of the Nov. 27 target action date, allows the use of neladalkib for patients with advanced disease who have undergone prior lines of treatment for unresectable tumors. To keep the approval, GSK will need to confirm the drug’s clinical benefit in a confirmatory study. Neladalkib will be marketed under the brand name Nelkarmi, according to a Tuesday announcement.

Sign up for Blog Updates